Adaptimmune stock plunges after announcing Nasdaq delisting plans
Director Booth indirectly sells Sionna Therapeutics (NASDAQ:SION) shares worth approximately $5.9 million between October 10 and October 15. The sales, executed under 10b5-1 trading plans, involved multiple transactions with prices ranging from $29.95 to $31.12, near the stock’s 52-week high of $31.47. The company’s shares have shown remarkable strength, gaining over 220% in the past six months.
The sales were conducted in two separate transactions. The first, executed by Atlas Venture Fund XI, L.P., involved the sale of 157,986 shares for a total value of $4,909,374. The second, executed by Atlas Venture Opportunity Fund II, L.P., involved the sale of 33,011 shares for a total value of $1,030,409. With a market capitalization of $1.32 billion and an "GREAT" financial health score according to InvestingPro, Sionna maintains strong institutional interest, with analysts setting price targets between $22 and $46.
Following these transactions, Atlas Venture Fund XI, L.P. indirectly holds 2,619,185 shares of Sionna Therapeutics , while Atlas Venture Opportunity Fund II, L.P. indirectly holds 751,664 shares. Discover more insights and 11 additional ProTips for SION on InvestingPro.
In other recent news, Sionna Therapeutics has announced the initiation of a Phase 1 trial for its novel cystic fibrosis treatment combinations. The trial involves SION-451, a first-in-class NBD1 stabilizer, in dual combinations with SION-2222 and SION-109. This study aims to evaluate the safety, tolerability, and pharmacokinetics of these combinations in healthy volunteers. Additionally, Guggenheim has reiterated its Buy rating for Sionna Therapeutics with a $45 price target, following the company’s second-quarter 2025 financial results. The firm noted positive topline Phase I safety and pharmacokinetic data, with plans to advance NBD1 stabilizers SION-719 and SION-451 into further clinical development. RBC Capital has also initiated coverage on Sionna Therapeutics with a Sector Perform rating and a $22 price target. Analyst Brian Abrahams from RBC Capital highlighted the potential of Sionna’s CFTR modulators to establish the company as a significant player in the cystic fibrosis space. These developments provide insights into Sionna’s ongoing efforts and strategic direction in advancing its treatment pipeline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.